6-[(2-{[4-(2,4-Dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino}ethyl)amino]nicotinonitrile(CAS: 252917-06-9)

The compound is subject to the Globally Harmonized System of Classification and Labelling of Chemicals (GHS) regulations, REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals) in the EU, and FDA/EPA registration requirements for specific uses. It is important to consult the current versions of these guidelines for detailed handling and safety information.

There are several alternatives that can be used in the synthesis of this compound, such as related analogs like 6-[(2-{[4-(2,4-dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino}ethyl)amino]nicotinamide, or isomers with slight structural modifications. Common alternative reagents include 2,4-dichlorophenyl derivatives and 5-methyl-1H-imidazol-2-yl groups.

The market for this compound shows steady growth, driven by its applications in pharmaceutical research and development. Emerging research trends focus on its potential as a therapeutic agent, particularly in treating certain types of cancer. Additionally, there is increasing interest in its synthesis and use in novel drug discovery projects.

Waste containing this compound should be collected in appropriate containers and stored in a secure, well-ventilated area. For disposal, it is recommended to use professional waste disposal services that specialize in hazardous chemical waste. Proper incineration or chemical neutralization methods should be employed, followed by appropriate environmental monitoring to ensure compliance with local regulations and environmental protection standards.